Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Bio-Rad Laboratories, Inc. reported revenue of $2.58B, up 0.7% year over year. Operating margin was 1.8% and net margin 29.4%, on a free-cash-flow margin of 14.5% with capital expenditure at 6.1% of revenue. Every figure is computed directly from BIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2.58B | 1.8% | 29.4% |
| FY2024 | $2.57B | 10.5% | -71.9% |
| FY2023 | $2.67B | 12.6% | -23.9% |
| FY2022 | $2.80B | 17.2% | -129.5% |
| FY2021 | $2.92B | 17.1% | 145.6% |
How does BIO compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: A · AEHR · AERG · AEVA · AIRI · ALGN
See BIO benchmarked against two sector peers (free) →
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.